drugset / Trial / NCT01346969

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

NCT01346969 ↗

Phase 2 Completed 68 enrolled Pfizer
RandomizedDouble-blindTreatment

Summary

The study will investigate the efficacy of various doses and regimens of EXC 001 in reducing skin scarring in subjects undergoing revision of scars from prior surgery. The study will also evaluate the safety and tolerability of EXC 001 and placebo.

Timeline

Start
2011-06-01
Primary completion
2012-04-16
Completion
2012-04-16

Drugs

EvaluationDrugModalityDoseRoute
Comparator EXC 001 Unknown — Other

Indications